

A randomised study of oral versus intravenous chemotherapy in poor prognosis small cell lung cancer (SCLC)

Submission date 01/07/2001	Recruitment status Stopped	☐ Prospectively registered ☐ Protocol
Registration date 01/07/2001	Overall study status Stopped	☐ Statistical analysis plan ☒ Results
Last Edited 13/06/2014	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number

TR9SCLC

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Lung (small cell)

Interventions

1. Regimen A: Chemotherapy, oral etoposide repeated every 3 weeks for six courses.
2. Regimen B: Multi-drug chemotherapy, CAV (cyclophosphamide, adriamycin, vincristine) alternating every 3 weeks with PE (etoposide, cisplatin). A total of six courses, three with each drug combination.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/12/2000

Reason abandoned (if study stopped)

Objectives no longer viable

Eligibility**Key inclusion criteria**

1. Histologically or cytologically proven SCLC
2. Patients with extensive disease and poor prognosis, i.e., Eastern Cooperative Oncology Group

(ECOG) performance 2 or 3 or alkaline phosphatase >1.5 upper limit normal range
3. Patients 75 years and over, whatever stage of disease, deemed fit for randomisation
4. No previous malignancy, except non-melanomatous skin cancer in the preceding 3 years
5. No medical contraindications to treatment
6. Adequate renal function

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1997

Date of final enrolment

31/12/2000

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information**Organisation**

UK Co-ordinating Committee for Cancer Research (UKCCCR)

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Not defined

Funder Name

Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	31/08/1996		Yes	No